BRACAnalysisCDx-logo
Gene Analysis

BRACAnalysis CDx®

BRACAnalysis CDx® – Confidently Recommend an Appropriate PARP Inhibitor with Fast and Accurate BRCA1/2 Results

 

Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer. BRACAnalysis CDx® was designed to quickly provide accurate results so you can confidently recommend the next treatment for your patient without delay.

Companion diagnostic indications

Tumor TypeBiomarkerTherapy
Breast CancerDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genesLynparza® (olaparib)
Talzenna® (talazoparib)
Ovarian CancerDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genesLynparza® (olaparib)-
treatment/maintenance
Rubraca® (rucaparib)
Pancreatic CancerDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genesLynparza® (olaparib)
Prostate CancerDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genesLynparza® (olaparib)

For more information please call us or visit www.myriad-oncology.com